

Center for Biomedical Innovation (CBI)

 consortiapedia.fastercures.org/consortia/cbi/

Research Areas



Tool Development

Resource



Product Development

At a Glance

- Status: **Active Consortium**
- Year Launched: **2005**
- Initiating Organization: **Massachusetts Institute of Technology**
- Initiator Type: **Academia**
- Location: **North America**

Abstract

The Center for Biomedical Innovation (CBI) manages several consortia that address a variety of challenges in the global biomedical industry by developing, testing, and disseminating new knowledge and tools designed for real-world application through the following programs: the Biomanufacturing Program (BioMAN), the Consortium on Adventitious Agents in Biomanufacturing (CAACB), and New Drug Development Paradigms (NEWDIGS).

Mission

CBI's mission is to improve global health by overcoming obstacles to the development and implementation of biomedical innovation. CBI provides a safe and transparent environment for collaborative research among industry, academia, and government, and draws on the expertise of the Massachusetts Institute of Technology's (MIT) Schools of Engineering, Science, and Management, as well as the Harvard-MIT Division of Health Sciences and Technology (HST).

CBI manages the following consortia:

BioManufacturing (BioMAN)

BioMAN is a collaborative research and educational program in biotherapeutic manufacturing. Its objective is to develop new knowledge, science, technologies, and strategies that advance the manufacture and global delivery of high-quality biopharmaceuticals. BioMAN activities bring together thought leaders from industry, the government (e.g., U.S. Food and Drug Agency), and academia and involve faculty from across the Schools of Science, Engineering, and Management at MIT.

Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB)

CAACB's mission is to develop a comprehensive understanding of adventitious agents encountered in biomanufacturing, the sources of such agents, and a systematic, risk-based analysis of the most effective strategies and technologies to prevent contamination.

NEW Drug Development ParaDIGmS (NEWDIGS)

NEWDIGS focuses on transforming the current global pharmaceutical innovation ecosystem to more reliably and sustainably deliver new, better, and affordable drugs to the right patients faster. System re-engineering projects are designed and executed with input from industry; regulators from the United States, Europe, Singapore, and Canada; payers and health technology assessment officials; and providers, patients, and academic researchers from MIT, Harvard, and other leading academic institutions.

Consortium History

CBI was formed in 2005 as a collaboration among the School of Engineering, the MIT Sloan School of Management, the School of Science, and the Harvard-MIT Division of Health Sciences and Technology (HST) to address the challenges within the pharmaceutical, biotechnology, diagnostics, and medical devices industries with respect to innovation, productivity, and costs and predicting and managing risks.

CBI merged with MIT's Program on the Pharmaceutical Industry (POPI) in 2008. POPI was founded in 1991 with a major grant from the Alfred P. Sloan Foundation to promote research and educational activities on issues related to competitiveness, performance, and productivity in the pharmaceutical field.

Financing

CBI receives funding from the government, industry, and philanthropic organizations. CBI received MIT internal start-up support from the School of Science, the School of Engineering, the MIT Sloan School of Management, the Office of the Provost, and the Office of the Vice President for Research and Associate Provost. The consortium has been successful in obtaining additional grants from MTC/JAII and the Merck Company Foundation to support the development of its business plan and other launch activities and to support research efforts in clinical trials and stratified medicine. In addition, six founding consortium members contribute membership fees to support CBI's research, educational, and administrative activities.

Impact/Accomplishment

Accomplishments are listed on the homepage at <http://cbi.mit.edu/>

Links/Social Media Feed

Homepage <http://cbi.mit.edu>

Points of Contact

Stacy L. Springs, Ph.D.

Director, BioMAN

Executive Director, Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB)

phone: 617-253-3084

email: ssprings@mit.edu

Sponsors & Partners

Participant/Sponsor

Alfred P. Sloan Foundation

Alnylam Pharmaceuticals

Amgen
Aquafine UV
Asahi Kasei Bioprocess
Baxter Pharmaceuticals
Bill and Melinda Gates Foundation
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Eli Lilly & Co.
EM.D. Millipore
Genzyme
Georgetown University
Histogenics
Kauffman Foundation
Latham Biopharm Group
Life Technologies
Massachusetts Institute of Technology
MedImmune
Metabolix
Northeastern University
Novartis
Pall Corporation
Pfizer
Rensselaer
Roche/Genentech
Sanofi
Sanofi Pasteur
Sanofi/Genzyme
Shire
Sigma-Aldrich
U.S. Food and Drug Administration
University of Prince Edward Island

Updated: **04/14/2016**

